A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding

详细信息    查看全文

• 作者：Rosarin Sruamsiri (1)
  Piyameth Dilokthornsakul (1)
  Chayanin Pratoomsoot (2)
  Nathorn Chaiyakunapruk (1) (3) (4) (5)
  
• 刊名：PharmacoEconomics
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：32
• 期：8
• 页码：801-813
• 全文大小：439 KB
• 参考文献：1. Millan R. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1981;304(19):1135-7. CrossRef
  2. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995-008. CrossRef
  3. Bolton-Maggs PH, Moon I. Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet. 1997;350(9078):620-. CrossRef
  4. Zeller B, Helgestad J, Hellebostad M, Kolmannskog S, Nystad T, Stensvold K, et al. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol. 2000;17(7):551-. CrossRef
  5. Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer. 2008;51(4):513-. CrossRef
  6. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-6. CrossRef
  7. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin N Am. 2010;24(1):249-3. CrossRef
  8. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-0.
  9. Blanchette VS, Carcao M. Childhood acute immune thrombocytopenic purpura: 20?years later. Semin Thromb Hemost. 2003;29:605-7. CrossRef
  10. Neunert CE, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-07. CrossRef
  11. Provan D, Nokes T, Agrawal S, Winer J, Wood P. Clinical guidelines for immunoglobulin use. Department of Health, NHS, UK; 2008.
  12. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(Suppl 1):S9-6. CrossRef
  13. British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120:574-6. CrossRef
  14. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-0.
  15. Condino-Neto A, Franco JL, Trujillo-Vargas C, Espinosa-Rosales FJ, Leiva LE, Rodriguez-Quiroz F, et al. Critical issues and needs in management of primary immunodeficiency diseases in Latin America. Allergol Immunopathol (Madr). 2011;39(1):45-1. CrossRef
  16. National Drug Committee. National list of essential medicine 2012. 2013. http://www.nlem.in.th/sites/default/files/essential_book.pdf. Accessed 26 Aug 2013.
  17. Roseman CB, Patrick WK, Tucker RV. Health technology assessment: a policy-relevant technology diffusion model for emerging economies of the Asia and Pacific region. Asia Pac J Public Health. 1991;5(1):10-. CrossRef
  18. Sivalal S. Health technology assessment in the Asia Pacific region. Int J Technol Assess Health Care. 2009;25(Suppl 1):196-01. CrossRef
  19. Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai Health Technology Assessment Guideline. J Med Assoc Thai 2008;91(Suppl 2):S1–S88.
  20. Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77(1):31-.
  21. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133(3):334-. CrossRef
  22. Beck C, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147:521-. CrossRef
  23. DerSimonian RLN. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-8. CrossRef
  24. Hemmila MR, Foley DS, Castle VP, Hirschl RB. The response to splenectomy in pediatric patients with idiopathic thrombocytopenic purpura who fail high-dose intravenous immune globulin. J Pediatr Surg. 2000;35(6):967-1. CrossRef
  25. Fabris F, Cordiano I, Girolami A. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;337:1088-.
  26. Schneider P, Wehmeier A, Schneider W. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;337:1087-. CrossRef
  27. Kwon HC, Moon CH, Cho YR, Kim MC, Kim KH, Han JY, et al. Prognostic factors of response to laparoscopic splenectomy in patients with idiopathic thrombocytopenic purpura. J Korean Med Sci. 2005;20(3):417-0. CrossRef
  28. Law C, Marcaccio M, Tam P, Heddle N, Kelton JG. High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med. 1997;336(21):1494-. CrossRef
  29. Hollander LL, Leys CM, Weil BR, Rescorla FJ. Predictive value of response to steroid therapy on response to splenectomy in children with immune thrombocytopenic purpura. Surgery. 2011;150(4):643-. CrossRef
  30. Mantadakis E, Buchanan GR. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2000;22(2):148-3. CrossRef
  31. Aronis S, Platokouki H, Mitsika A, Haidas S, Constantopoulos A. Seventeen years of experience with chronic idiopathic thrombocytopenic purpura in childhood. Is therapy always better? Pediatr Hematol Oncol. 1994;11(5):487-8. CrossRef
  32. Ko?ak U, Aral YZ, Kaya Z, Oztürk G, Gürsel T. Evaluation of clinical characteristics, diagnosis and management in childhood immune thrombocytopenic purpura: a single center’s experience. Turk J Pediatr. 2007;49(3):250-.
  33. Belletrutti M, Ali K, Barnard D, Blanchette V, Chan A, David M, et al. Chronic immune thrombocytopenic purpura in children: a survey of the Canadian experience. J Pediatr Hematol Oncol. 2007;29(2):95-00. CrossRef
  34. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122-. CrossRef
  35. Glanz J, France E, Xu S, Hayes T, Hambidge S. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pedatrics. 2008;121(3):e506-2. CrossRef
  36. Health Information Group. Bureau of Health Policy and Strategy MoPHT. Public Health Statistics A.D.2009. http://203.157.19.191/input_bps.htm.
  37. Aronis S, Platokouki H, Avgeri M, Pergantou H, Keramidas D. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr. 2004;93:638-2. CrossRef
  38. Donato H, Picon A, Rapetti MC. Splenectomy and spontaneous remission in children with chronic idiopathic thrombocytopenic purpura. Pediatr Blood Cancer. 2006;47:373-. CrossRef
  39. Wang T, Xu M, Ji L. Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China. Acta Haematol. 2006;115:39-5. CrossRef
  40. Yong M, Thomsen RW, Schoonen WM, Farkas DK, Riis A, Fryzek JP, et al. Mortality risk in splenectomised patients: a Danish population-based cohort study. Eur J Intern Med. 2010;21(1):12-. CrossRef
  41. Riewpaiboon A. Standard cost lists for health technology assessment. Bangkok: Faculty of Pharmacy, Mahidol University; 2010.
  42. Bank of Thailand. Exchange rate. 2013. http://www2.bot.or.th/statistics/BOTWEBSTAT.aspx?reportID=145&language=TH. Accessed 30 Dec 2013.
  43. Bank of Thailand. EC_EI_027: Thailand’s macro economic indicators 1. 2012. http://www2.bot.or.th/statistics/ReportPage.aspx?reportID=409&language=eng. Accessed 8 July 2013.
  44. Ministry of Public Health Thailand. Drug Medical Supply and Information Center (DMSIC). http://dmsic.moph.go.th/price.htm. Accessed 26 Dec 2012.
  45. Drummond MF, Mark JS, George WT. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
  46. Ministry of Public Health Network of Unit Cost. Unit cost manual for hospital: MUCC; 2011.
  47. Tongsiri S, Cairns J. Estimating population-based values for EQ-5D health states in Thailand. Value Health. 2011;14(8):1142-. CrossRef
  48. Snyder CF, Mathias SD, Cella D, Isitt JJ, Wu AW, Young J. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24(10):2767-6. CrossRef
  49. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203-0. CrossRef
  50. Thai Working Group on Health Technology Assessment Guidelines in Thailand. Thai Health Technology Assessment Guideline. J Med Assoc Thai. 2008;91(Suppl.2):S1–S88.
  51. Meeyai A, Kotirum S, Praditsitthikorn N, Kulpeng W, Cooper B, Teerawattananon Y. Cost-utility analysis of seasonal influenza vaccine among school children in Thailand. Bangkok: Health Intervention and Technology Assessment Program (HITAP); 2013.
  52. Meeting of Subcommittee for Development of the National List of Essential Drugs. Nonthaburi: Food and Drug Administration; 2012. p. 7.
  53. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006.
  54. Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thail. 2008;91(Suppl 2):S59-5.
  55. Blackhouse G, Xie F, Levine MA, Campbell K, Assasi N, Gaebel K, et al. Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. J Popul Ther Clin Pharmacol. 2012;19(2):e166-8.
  56. O’Brien SH, Ritchey AK, Smith KJ. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer. 2007;48(2):173-0. CrossRef
  57. Kühne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143(5):605-. CrossRef
  58. Donato H, Picón A, Martinez M, Rapetti MC, Rosso A, Gomez S, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer. 2009;52(4):491-. CrossRef
  59. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133(3):334-. CrossRef
  60. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344(8924):703-. CrossRef
  
• 作者单位：Rosarin Sruamsiri (1)
  Piyameth Dilokthornsakul (1)
  Chayanin Pratoomsoot (2)
  Nathorn Chaiyakunapruk (1) (3) (4) (5)
  
  1. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Center of Pharmaceutical Outcomes Research, Naresuan University, Phitsanulok, Thailand
  2. Faculty of Public Health, Naresuan University, Phitsanulok, Thailand
  3. School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 46150, Bandar Sunway, Selangor, Malaysia
  4. School of Population Health, University of Queensland, Brisbane, Australia
  5. School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA
  
• ISSN：1179-2027

文摘

Background Although the international guideline recommends intravenous immunoglobulin (IVIG) as the first-line treatment for childhood idiopathic thrombocytopenia purpura (ITP) with life-threatening bleeding, ITP patients may not be able to access IVIG because of the limitation in health benefit packages especially in developing countries. There remains an important policy question as to whether IVIG used as a first-line treatment is worth the money spent. Thus, the objective of this study was to perform a cost-effectiveness analysis of adding IVIG to the standard treatment of platelet transfusion and corticosteroids, for the treatment of childhood ITP with life-threatening bleeding in the context of Thailand. Methods A cost-effectiveness analysis using a hybrid model consisting of a decision tree and Markov models was conducted with a societal perspective. The effectiveness and utility parameters were determined by systematic reviews, while costs and mortality parameters were determined using a retrospective electronic hospital database analysis. All costs were presented in 2012 US$. The discount rate of 3?% was applied for both costs and outcomes. One-way and probabilistic sensitivity analyses were also performed. Results The incremental cost-effectiveness ratio (ICER) was $3,172 per quality-adjusted life-year gained ($/QALY) for the addition of IVIG versus standard treatment alone. The probability of response to corticosteroids was the most influential parameter on ICER. According to the willingness-to-pay of Thailand, of approximately $3,861/QALY, the probability of IVIG being cost effective was 33?%. Conclusions The addition of IVIG to standard treatment in the treatment of childhood ITP with life-threatening bleeding is possibly a cost-effective intervention in Thailand. However, our findings were highly sensitive. Policy makers may consider our findings as part of the information for their decision making